Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -28.99% is in line with its 5-year average of -30.04%, around the middle of its 5-year range (-57.51%–-0.73%).
7.80% above its 12-month average of -31.44%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -34.98%.
NET PROFIT MARGIN
-28.99%
NET PROFIT MARGIN AVG TTM
-31.44%
NET PROFIT MARGIN AVG 3Y
-36.30%
NET PROFIT MARGIN AVG 5Y
-30.04%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.80%
CURRENT VS 3Y AVG
+20.14%
CURRENT VS 5Y AVG
+3.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-8182.86%
vs the sector median at left
Treace Medical Concepts, Inc.
Market Cap
$259.49M
Net Profit Margin
-28.99%
TTM Avg
-31.44%
3Y Avg
-36.30%
5Y Avg
-30.04%
Market Cap
$259.56M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$259.14M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$259.12M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-2265.94%
5Y Avg
-2185.44%
Market Cap
$258.63M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$261.27M
Net Profit Margin
-568.80%
TTM Avg
-845.08%
3Y Avg
-422.54%
5Y Avg
-626.87%
Market Cap
$261.43M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$256.47M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$262.92M
Net Profit Margin
-62.59%
TTM Avg
-99.90%
3Y Avg
-225.27%
5Y Avg
-207.41%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $259.49M | -28.99% | -31.44% | -36.30% | -30.04% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | -43.70% | -35.13% | -15.36% | -13.33% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.00% | 0.00% | -2265.94% | -2185.44% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | -568.80% | -845.08% | -422.54% | -626.87% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| AC Immune S.A. (ACIU)vs › | $256.47M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -62.59% | -99.90% | -225.27% | -207.41% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -3.14% | -28.33% | -34.54% | -25.62% |
Operating Margin
-26.2%
Net Profit Margin
-29.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -34.98% |
| 2026-03-31 | -38.05% |
| 2025-12-31 | -15.03% |
| 2025-09-30 | -32.44% |
| 2025-06-30 | -36.71% |
| 2025-03-31 | -30.29% |
| 2024-12-31 | -0.73% |
| 2024-09-30 | -34.07% |
| 2024-06-30 | -47.70% |
| 2024-03-31 | -36.54% |
| 2023-12-31 | -10.10% |
| 2023-09-30 | -42.99% |
| 2023-06-30 | -29.25% |
| 2023-03-31 | -31.89% |
| 2022-12-31 | -8.86% |
| 2022-09-30 | -36.71% |
| 2022-06-30 | -57.51% |
| 2022-03-31 | -31.11% |
| 2021-12-31 | -19.79% |
| 2021-09-30 | -29.69% |
| 2021-06-30 | -24.61% |
| 2021-03-31 | -13.00% |
| 2020-12-31 | 10.65% |
| 2020-09-30 | -18.61% |
| 2020-06-30 | -25.49% |
| 2020-03-31 | -14.28% |
